OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
Checked against the public recordLast updated Dec 26, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Interventions being studied
- Drug: erlotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Must have histologically or cytologically confirmed stage IIIB or IV NSCLC treated with 1-2 platinum- or taxane-containing regimens * Measurable disease * May have had prior surgery \& external beam radiation * African American * 18 years or older Exclusion Criteria: * Known brain mets * Prior treatment with EGFR targeting therapies * Pregnant/lactating women
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Ohio State UniversityColumbus, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 26, 2017. Always confirm current availability with the study team.